Hospital-wide ELectronic medical record evaluated computerised decision support system to improve outcomes of Patients with staphylococcal bloodstream infectio

Not Applicable

• Conditions: A41.0; A41.1; Sepsis due to Staphylococcus aureus; Sepsis due to other specified staphylococcus

• Registration Number: DRKS00014320
• Lead Sponsor: niversitätsklinikum Jena

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-05-06
• Study Completion: 2023-12-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 7895

Inclusion Criteria

Staphylococcus spp. bacteremia

Exclusion Criteria

Patients from psychiatric wards, pediatric wards and obstetric wards. If treated according to KNS arm: death of patient within 72h after collection of first blood culture.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Coprimary endpoints (confirmatory test in the hierarchical order given here):<br>- mortality and relapse rate due to S. aureus within 90 days in the SAB arm (non-inferiority test) and<br>- the cumulative consumption of vancomycin in the CNS arm (superiority test)

Secondary Outcome Measures

Name	Time	Method
- acute renal failure (KDIGO clinical practice guideline for acute kidney injury)<br>- cumulative consumption of vancomycin, linezolid, teicoplanin, daptomycin, rifampicin, fosfomycin, flucloxacillin, cefazolin<br>- incoming blood culture sets per institution and year<br>- estimation of treatment costs based on ID consultation times and frequencies (only for complicated SAB) as well as technical and process-oriented endpoints from questionnaires (user survey)<br><br>